{"organizations": [], "uuid": "02e7a95f0cd70e178b71c71da38edb723280ca12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180212&t=2&i=1230628507&w=1200&r=LYNXMPEE1B0LO", "site_section": "http://feeds.reuters.com/reuters/healthNews\r", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-norway-biogen/norway-to-buy-biogens-spinraza-medicine-broadcaster-nrk-idUSKBN1FW0TR", "country": "US", "domain_rank": 408, "title": "Norway to buy Biogen's Spinraza medicine: broadcaster NRK", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T12:07:00.000+02:00", "replies_count": 0, "uuid": "02e7a95f0cd70e178b71c71da38edb723280ca12"}, "author": "", "url": "https://www.reuters.com/article/us-norway-biogen/norway-to-buy-biogens-spinraza-medicine-broadcaster-nrk-idUSKBN1FW0TR", "ord_in_thread": 0, "title": "Norway to buy Biogen's Spinraza medicine: broadcaster NRK", "locations": [], "entities": {"persons": [], "locations": [{"name": "norway", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nrk", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "min read  oslo", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "biogen inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.\nSpinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only.\n($1 = 7.9511 Norwegian crowns)\nReporting by Gwladys Fouche, editing by Terje Solsvik\n ", "external_links": [], "published": "2018-02-12T12:07:00.000+02:00", "crawled": "2018-02-12T12:18:31.019+02:00", "highlightTitle": ""}